Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

IVUS in Acute Coronary Syndrome: A New Requirement?

The use of intravascular ultrasound (IVUS) has seen exponential growth across registries over the years, combined with mounting and increasingly robust evidence. The fact that it will enable us to characterize plaque morphology and extension prior the intervention, and even assess stent expansion post intervention, has turned it into a pillar of our efforts to improve complicated outcomes, outweighing angiography guided PCI in multiple randomized studies. 

El uso del ultrasonido intravascular en la angioplastia de tronco no protegido se asocia con mejores resultados en comparación con la angioplastia guiada solo por angiografía.

However, in the clinical context of acute coronary syndrome (ACS) no evidence is yet strong enough for us to claim it is essential. 

Even though in most ACS patients we will normally be able to identify the culprit lesion and perform an angioplasty, a not insignificant percentage of patients will raise questions, such as those presenting clinical heterogeneity, with no changes in ECG and even an absence of segmentary alterations in the echocardiogram. In these cases, a 30% might lack a culprit lesion and around 10% will present multiple lesions potentially culprit. Which is why an imaging diagnostic tool such as IVUS might be able to answer these questions

In this observational study recently published in AHA, researchers set to find out whether the use of IVUS has any clinical impact in the treatment of ACS in the long term. 

Read also: IVUS vs iFR for Left Main Decision Making.

They analyzed ACS patients without ST elevation MI, intervened with second generation stents, from the Korea Acute Myocardial Infarction Registry-National Institutes of Health (KAMIR-NIH) followed up at 3 years, between 2011 and 2015. Primary end point was target lesion failure (TLF) at 3 years, which is a combination of cardiac death, myocardial infarction, and ischemia driven revascularization of culprit lesion.  

Of the overall studied population (n=9007), 7120 patients received a second-generation stent guided by angiography, and in 1887 patients the intervention was guided by IVUS. 

Researchers observed the risk of TLF at 3 years was significantly lower in the IVUS group vs. the angiography guided group (HR, 0.59, 0.47-0.73, p<0.001), mainly at the expense of cardiac mortality and target vessel myocardial infarction. 

Read also: IVUS vs OCT to Guide PCI: Which Should We Choose?

Such a drop in primary end point maintained across multiple sensitivity analysis and across different pre-specified subgroups. The same happened with secondary end points of cardiac mortality (HR=0.56, 0.42-0.73 p<0.001) and MACE (HR=0.76, 0.66-0.87, p<0.001).

Authors’ Conclusions

With the limitations of a randomized study, sensitivity and propensity analysis were carried out, resulting in significantly reduced TLF at 3 years, at the expense of hard end points such as morality and target vessel myocardial infarction. These outcomes suggest an important role of IVUS in the treatment of acute coronary syndrome.  

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Membro do Conselho Editorial da SOLACI.org

Original Title: Role of Intravascular Ultrasound-Guided Percutaneous Coronary Intervention in Optimizing Outcomes in Acute Myocardial Infarction.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...